BRPI1015941A2 - formulações de comprimido de 3-cianoquinolina e uso das mesmas. - Google Patents

formulações de comprimido de 3-cianoquinolina e uso das mesmas.

Info

Publication number
BRPI1015941A2
BRPI1015941A2 BRPI1015941A BRPI1015941A BRPI1015941A2 BR PI1015941 A2 BRPI1015941 A2 BR PI1015941A2 BR PI1015941 A BRPI1015941 A BR PI1015941A BR PI1015941 A BRPI1015941 A BR PI1015941A BR PI1015941 A2 BRPI1015941 A2 BR PI1015941A2
Authority
BR
Brazil
Prior art keywords
cyanoquinoline
tablet formulations
formulations
tablet
cyanoquinoline tablet
Prior art date
Application number
BRPI1015941A
Other languages
English (en)
Inventor
Arwinder Nagi
Goldi Kaul
Krishnendu Ghosh
Ramarao Chatlapalli
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI1015941A2 publication Critical patent/BRPI1015941A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1015941A 2009-07-02 2010-06-30 formulações de comprimido de 3-cianoquinolina e uso das mesmas. BRPI1015941A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22253709P 2009-07-02 2009-07-02
PCT/US2010/040555 WO2011002857A2 (en) 2009-07-02 2010-06-30 3-cyanoquinoline tablet formulations and uses thereof

Publications (1)

Publication Number Publication Date
BRPI1015941A2 true BRPI1015941A2 (pt) 2016-04-19

Family

ID=42732381

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015941A BRPI1015941A2 (pt) 2009-07-02 2010-06-30 formulações de comprimido de 3-cianoquinolina e uso das mesmas.

Country Status (15)

Country Link
EP (1) EP2448563A2 (pt)
JP (1) JP2011012063A (pt)
KR (1) KR20120046216A (pt)
CN (1) CN102470109A (pt)
AR (1) AR077546A1 (pt)
AU (1) AU2010266342A1 (pt)
BR (1) BRPI1015941A2 (pt)
CA (1) CA2766067A1 (pt)
IL (1) IL217298A0 (pt)
MX (1) MX2012000048A (pt)
RU (1) RU2011152105A (pt)
SG (1) SG177309A1 (pt)
TW (1) TW201113050A (pt)
WO (1) WO2011002857A2 (pt)
ZA (1) ZA201200366B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
FI4066821T3 (fi) 2009-11-09 2025-05-13 Wyeth Llc Neratinibimaleaatin tablettiformulaatioita
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
EP3439639A1 (en) * 2016-04-08 2019-02-13 Shionogi & Co., Ltd. Stabilized solid dosage form
JP7086938B2 (ja) 2017-03-31 2022-06-20 日精エー・エス・ビー機械株式会社 樹脂製容器

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
PL208114B1 (pl) * 2002-02-26 2011-03-31 Astrazeneca Ab Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
CA2535385A1 (en) 2003-08-19 2005-03-03 Wyeth Holdings Corporation Process for the preparation of 4-amino-3-quinolinecarbonitriles
ATE428421T1 (de) * 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
WO2007005462A1 (en) * 2005-07-01 2007-01-11 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
WO2008053295A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid
CN101224185A (zh) * 2007-12-11 2008-07-23 山东蓝金生物工程有限公司 一种治疗实体肿瘤的伯舒替尼缓释植入剂

Also Published As

Publication number Publication date
WO2011002857A2 (en) 2011-01-06
AR077546A1 (es) 2011-09-07
EP2448563A2 (en) 2012-05-09
SG177309A1 (en) 2012-02-28
KR20120046216A (ko) 2012-05-09
IL217298A0 (en) 2012-02-29
CN102470109A (zh) 2012-05-23
RU2011152105A (ru) 2013-08-10
WO2011002857A3 (en) 2011-03-10
JP2011012063A (ja) 2011-01-20
TW201113050A (en) 2011-04-16
AU2010266342A1 (en) 2012-01-19
MX2012000048A (es) 2012-01-27
ZA201200366B (en) 2012-10-31
CA2766067A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
FR25C1035I1 (fr) Formulations de comprimés de maléate de nératinib
LTPA2020003I1 (lt) Dvisluoksnės tabletės formuluotės
BRPI1008709A2 (pt) composições e usos das mesmas.
BR112012013148A2 (pt) formulação farmacêutica e uso
BR112012005736A2 (pt) di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas
BRPI1014160A2 (pt) Formulações de nanopartículas e aplicações das mesmas
BR112012011733A2 (pt) formulações de comprimido de liberação imediata
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BR112012003792A2 (pt) gel tópico, e, uso do gel tópico.
SMT201400069B (it) Formulazione farmaceutica
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI1016117A2 (pt) derivados de isoxazol-isoxazol e isoxasol-isotiazol.
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BRPI1014898A2 (pt) cosmético capilar.
BRPI1014388A2 (pt) preparação de sólido.
ZA201200366B (en) 3-cyanoquinoline tablet formulations and uses thereof
BRPI1011036A2 (pt) uso
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BRPI0908455A2 (pt) formulações de flibanserina
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0907700A2 (pt) Imidazopiridazinas como inibidores par1, produção das mesmas e uso como medicamentos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]